{
    "clinical_study": {
        "@rank": "45290", 
        "arm_group": {
            "arm_group_label": "Insulin Peglispro", 
            "arm_group_type": "Experimental", 
            "description": "Insulin peglispro is given subcutaneously once."
        }, 
        "brief_summary": {
            "textblock": "The main purpose of this study is to evaluate how the body processes the study drug known as\n      insulin peglispro and how the study drug affects blood sugar in healthy male Japanese\n      participants. This study will also evaluate safety of the study drug. The study will last up\n      to 46 days for each participant, not including screening."
        }, 
        "brief_title": "A Study of Insulin Peglispro in Healthy Male Japanese Participants", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants are overtly healthy male Japanese.\n\n          -  Participants have Body Mass Index (BMI) between 18.5 and 25.0 kilogram per square\n             meter (kg/m^2), inclusive.\n\n        Exclusion Criteria:\n\n          -  Participants have known allergies to insulin peglispro, related compounds.\n\n          -  Participants have a fasting venous blood glucose >108 milligram per deciliter (mg/dL)\n             (>6 millimole per liter [mmol/L])."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995526", 
            "org_study_id": "14682", 
            "secondary_id": "I2R-JE-BIDK"
        }, 
        "intervention": {
            "arm_group_label": "Insulin Peglispro", 
            "description": "Administered subcutaneously", 
            "intervention_name": "Insulin Peglispro", 
            "intervention_type": "Drug", 
            "other_name": "LY2605541"
        }, 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fukuoka", 
                    "country": "Japan", 
                    "zip": "812-0025"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Dose Study to Evaluate the Pharmacokinetics and Glucodynamics of Insulin Peglispro (LY2605541) in Healthy Male Japanese Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Japan: Institutional Review Board", 
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of Insulin Peglispro", 
                "safety_issue": "No", 
                "time_frame": "Day 1:  Predose up to 192 hours postdose"
            }, 
            {
                "measure": "Pharmacokinetics:  Area Under the Concentration Curve (AUC) of Insulin Peglispro", 
                "safety_issue": "No", 
                "time_frame": "Day 1:  Predose up to 192 hours postdose"
            }, 
            {
                "measure": "Glucodynamics: Maximum Glucose Infusion Rate (Rmax)", 
                "safety_issue": "No", 
                "time_frame": "Day1: Predose up to 36 hours post dose"
            }, 
            {
                "measure": "Glucodynamics: Total Amount of Glucose Infused (Gtot)", 
                "safety_issue": "No", 
                "time_frame": "Day1: Predose up to 36 hours post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995526"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}